Prostate Cancer

EGCG is the main green tea catechin, and prostate cancer is one of the most clinically advanced areas of EGCG research.

Overview

This literature includes prevention trials, biomarker-focused human work, and extensive pathway data tied to androgen signalling, IGF-1, and inflammation.

Key human data

• A randomised trial in men with high-grade prostatic intraepithelial neoplasia showed a strong reduction in progression to prostate cancer with green tea catechins

• Presurgical biomarker studies showed tissue-level changes in growth and invasion markers after Polyphenon E use

• Early work in castration-resistant disease showed tolerability and limited stabilisation signals

Key preclinical data

• EGCG suppresses androgen receptor signalling

• Reduces IGF-1, IGF-1R, COX-2, and iNOS-related pathways

• Inhibits PI3K/Akt/mTOR in androgen-sensitive and resistant models

Clinical positioning

Prostate cancer is one of the stronger EGCG settings, especially for early disease, chemoprevention, and recurrence-focused support.

References

Epigallocatechin-3-gallate (EGCG) prevents progression of prostate cancer in high-grade prostatic intraepithelial neoplasia
https://pubmed.ncbi.nlm.nih.gov/16331380/

Polyphenon E in men with localized prostate cancer: a presurgical biomarker trial
https://pubmed.ncbi.nlm.nih.gov/22328437/